Large‐volume residual disease (LVRD) > 1 cm vs NMRD
Progression‐free survival · women with advanced EOC after primary IDS
The review found no eligible studies for this question.
1 finding from 1 review
- Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found